PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Payment Arrangement, Expense, Tax Benefit
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Payment Arrangement, Expense, Tax Benefit of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for fiscal 2024 was $8.30M, a 15.28% increase from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for fiscal 2023 was $7.20M, a 24.14% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, expense, tax benefit for fiscal 2022 was $5.80M, a 23.40% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 3 month | Share-based Payment Arrangement, Expense, Tax Benefit 6 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month | Share-based Payment Arrangement, Expense, Tax Benefit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $2.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $2.40M derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $2.40M derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-06 | $6.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.40M 10-Q · filed 2026-08-06 | $4.40M 10-Q · filed 2026-08-06 | $6.40M derived: sum of 3 quarters · filed 2026-08-06 | $8.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-07 | $4.00M derived: sum of 2 quarters · filed 2026-05-07 | $6.00M derived: sum of 3 quarters · filed 2026-05-07 | $8.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.00M derived: sum of 2 quarters · filed 2026-02-27 | $6.10M derived: sum of 3 quarters · filed 2026-02-27 | $8.30M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-06 | $4.10M derived: sum of 2 quarters · filed 2025-11-06 | $6.30M 10-Q · filed 2025-11-06 | $8.10M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $2.10M 10-Q · filed 2025-08-04 | $4.30M 10-Q · filed 2025-08-04 | $6.10M derived: sum of 3 quarters · filed 2026-02-27 | $8.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $2.10M 10-Q · filed 2025-05-08 | $4.00M derived: sum of 2 quarters · filed 2026-02-27 | $5.90M derived: sum of 3 quarters · filed 2026-02-27 | $7.70M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.80M derived: sum of 2 quarters · filed 2026-02-27 | $5.60M derived: sum of 3 quarters · filed 2026-02-27 | $7.20M 10-K · filed 2026-02-27 |
| 2023-09-30 | $1.90M 10-Q · filed 2024-11-12 | $3.70M derived: sum of 2 quarters · filed 2024-11-12 | $5.30M 10-Q · filed 2024-11-12 | $6.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.80M 10-Q · filed 2024-08-08 | $3.40M 10-Q · filed 2024-08-08 | $4.70M derived: sum of 3 quarters · filed 2025-02-27 | $6.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.60M 10-Q · filed 2024-05-08 | $2.90M derived: sum of 2 quarters · filed 2025-02-27 | $4.40M derived: sum of 3 quarters · filed 2025-02-27 | $5.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.80M derived: sum of 2 quarters · filed 2025-02-27 | $4.30M derived: sum of 3 quarters · filed 2025-02-27 | $5.80M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-02 | $3.00M derived: sum of 2 quarters · filed 2023-11-02 | $4.50M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $1.50M 10-Q · filed 2023-08-03 | $3.00M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $1.40M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $4.70M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $4.30M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |